Evidence map›Paper›PMID 40946796›Full record

ArticleThe American journal of pathology2025

Role of PD-L1 in Regulatory T Cell-Mediated Suppression of Corneal Neovascularization.

Shima Dehghani, Manuel Chacon, Katayoon Forouzanfar, Seokjoo Lee, Akitomo Narimatsu, Rohan Bir Singh, Aytan Musayeva, Francesca Kahale, Sonia Anchouche, Neda Heydarian and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shima DehghaniDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Manuel ChaconDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Katayoon ForouzanfarDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Seokjoo LeeDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Akitomo NarimatsuDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Rohan Bir SinghDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Aytan MusayevaDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Francesca KahaleDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Sonia AnchoucheDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Neda HeydarianDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Shilpy BhullarDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Thomas H DohlmanDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Yihe ChenDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Tomas BlancoDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Reza DanaDepartment of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts. Electronic address: dana.locitr@gmail.com.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
MECHANISMS OF SENSITIZATION IN HIGH-RISK CORNEAL GRAFTSR01EY012963 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI DANA, REZA · 2000 to 2025
$15.1M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY012963
6 · The paper itself

Abstract

Corneal neovascularization (NV) leads to inflammation and fibrosis, thereby compromising visual acuity and corneal graft survival. Despite existing antiangiogenic therapies, clinical outcomes remain suboptimal. This study explores the antiangiogenic potential of regulatory T cells (Tregs) through programmed death-ligand 1 (PD-L1). In vitro tube formation assays were performed by co-culturing MS1 endothelial cells with Tregs. In addition, murine corneal suture-induced NV and high-risk corneal transplantation models were used to evaluate the effects of subconjunctival Treg injections in vivo. Wild-type (WT) Tregs inhibited endothelial tube formation, whereas PD-L1

Indexed as

B7-H1 AntigenCorneal NeovascularizationT-Lymphocytes, RegulatoryAnimalsCoculture TechniquesCorneal TransplantationEndothelial CellsMiceMice, Inbred C57BLMice, KnockoutVascular Endothelial Growth Factor AB7-H1 AntigenCd274 protein, mouseVascular Endothelial Growth Factor A

Identifiers

PMID40946796
PMCPMC12799401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.